Last reviewed · How we verify

Lidocaine Ropivacaine

TriHealth Inc. · FDA-approved active Small molecule

This combination of lidocaine and ropivacaine blocks sodium channels in nerve cell membranes to produce local anesthesia.

This combination of lidocaine and ropivacaine blocks sodium channels in nerve cell membranes to produce local anesthesia. Used for Local infiltration anesthesia, Regional anesthesia and nerve blocks, Topical/infiltrative anesthesia for surgical and dental procedures.

At a glance

Generic nameLidocaine Ropivacaine
Also known asNaropin, Ropivacaine HCL
SponsorTriHealth Inc.
Drug classLocal anesthetic (amide class)
TargetVoltage-gated sodium channels
ModalitySmall molecule
Therapeutic areaAnesthesia
PhaseFDA-approved

Mechanism of action

Both lidocaine and ropivacaine are amide-type local anesthetics that work by inhibiting sodium influx through voltage-gated sodium channels in nerve fibers, thereby preventing depolarization and conduction of action potentials. This dual-agent formulation combines the rapid onset of lidocaine with the longer duration of action and reduced systemic toxicity profile of ropivacaine. The combination is used to provide extended local anesthetic coverage for infiltration and regional anesthesia procedures.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results